ACM
RPRX icon

Aubrey Capital Management’s Royalty Pharma RPRX Stock Holding History

Aubrey Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,243
Closed -$346K – 66
2024
Q3 		$346K Sell
12,243
-13,216
-52% -$366K 0.13% 48
2024
Q2 		$536K Sell
25,459
-5,160
-17% -$143K 0.21% 44
2024
Q1 		$736K Sell
30,619
-2,472
-7% -$72.9K 0.26% 40
2023
Q4 		$926K Buy
+33,091
New +$909K 0.39% 41
2022
Q4 		– Sell
-15,600
Closed -$629K – 54
2022
Q3 		$629K Buy
15,600
+5,500
+54% +$235K 0.54% 26
2022
Q2 		$430K Hold
10,100
– – 0.35% 35
2022
Q1 		$394K Buy
+10,100
New +$397K 0.23% 47

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aubrey Capital Management's RPRX Position: Q4 2024 in Review

Aubrey Capital Management sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 12,243 shares — an estimated $346K sold.

Aubrey Capital Management first reported a position in RPRX in Q1 2022 and held it in 7 quarters. The position peaked at $926K in Q4 2023. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Aubrey Capital Management reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Aubrey Capital Management sold 12,243 Royalty Pharma shares in Q4 2024, an estimated $346K.
  • Aubrey Capital Management first reported a position in Royalty Pharma in Q1 2022 and held it in 7 quarters.
  • Aubrey Capital Management's Royalty Pharma position peaked at $926K in Q4 2023.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Aubrey Capital Management's 13F filing for Q4 2024, filed 29 Jan 2025.